NCT03789617 - A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2024

Conditions

EBV Associated Extranodal NK/T-cell LymphomaEBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma

Interventions

BIOLOGICAL

EBViNT Cell

"1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL~2. Administration: Inject intravenously over 30 minutes~3. Dosing schedule: Single dose"

Trial Locations (8)

NOT_YET_RECRUITING

National Cancer Center, Goyang-si

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

NOT_YET_RECRUITING

Inje Univ. Hosp, Pusan

RECRUITING

Pusan national Univ. Hosp., Pusan

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

NOT_YET_RECRUITING

Seoul Asan Medical center, Seoul

NOT_YET_RECRUITING

Severance hosp., Seoul

NOT_YET_RECRUITING

Ajou Univ Hosp., Suwon